Cargando…

Pharmacogenomics in type II diabetes mellitus management: Steps toward personalized medicine

Advances in genotype technology in the last decade have put the pharmacogenomics revolution at the forefront of future medicine in clinical practice. Discovery of novel gene variations in drug transporters, drug targets, effector proteins and metabolizing enzymes in the form of single-nucleotide pol...

Descripción completa

Detalles Bibliográficos
Autores principales: Avery, Peter, Mousa, Shaymaa S, Mousa, Shaker A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3513204/
https://www.ncbi.nlm.nih.gov/pubmed/23226037
_version_ 1782251900313272320
author Avery, Peter
Mousa, Shaymaa S
Mousa, Shaker A
author_facet Avery, Peter
Mousa, Shaymaa S
Mousa, Shaker A
author_sort Avery, Peter
collection PubMed
description Advances in genotype technology in the last decade have put the pharmacogenomics revolution at the forefront of future medicine in clinical practice. Discovery of novel gene variations in drug transporters, drug targets, effector proteins and metabolizing enzymes in the form of single-nucleotide polymorphisms (SNPs) continue to provide insight into the biological phenomena that govern drug efficacy and toxicity. To date, novel gene discoveries extracted from genome-wide association scans and candidate gene studies in at least four antidiabetic drug classes have helped illuminate possible causes of interindividual variability in response. Inadequate protocol guidelines for pharmacogenomics studies often leads to poorly designed studies, making it hard to formulate a definitive conclusion regarding the clinical relevance of the information at hand. These issues, along with the ethical, social, political, legislative, technological, and economic challenges associated with pharmacogenomics have only delayed its entry to mainstream clinical practice. On the other hand, these issues are being actively pursued and rapid progress is being made in each area which assures the possibility of gaining widespread acceptance in clinical practice.
format Online
Article
Text
id pubmed-3513204
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-35132042012-12-05 Pharmacogenomics in type II diabetes mellitus management: Steps toward personalized medicine Avery, Peter Mousa, Shaymaa S Mousa, Shaker A Pharmgenomics Pers Med Review Advances in genotype technology in the last decade have put the pharmacogenomics revolution at the forefront of future medicine in clinical practice. Discovery of novel gene variations in drug transporters, drug targets, effector proteins and metabolizing enzymes in the form of single-nucleotide polymorphisms (SNPs) continue to provide insight into the biological phenomena that govern drug efficacy and toxicity. To date, novel gene discoveries extracted from genome-wide association scans and candidate gene studies in at least four antidiabetic drug classes have helped illuminate possible causes of interindividual variability in response. Inadequate protocol guidelines for pharmacogenomics studies often leads to poorly designed studies, making it hard to formulate a definitive conclusion regarding the clinical relevance of the information at hand. These issues, along with the ethical, social, political, legislative, technological, and economic challenges associated with pharmacogenomics have only delayed its entry to mainstream clinical practice. On the other hand, these issues are being actively pursued and rapid progress is being made in each area which assures the possibility of gaining widespread acceptance in clinical practice. Dove Medical Press 2009-09-13 /pmc/articles/PMC3513204/ /pubmed/23226037 Text en © 2009 Avery et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
spellingShingle Review
Avery, Peter
Mousa, Shaymaa S
Mousa, Shaker A
Pharmacogenomics in type II diabetes mellitus management: Steps toward personalized medicine
title Pharmacogenomics in type II diabetes mellitus management: Steps toward personalized medicine
title_full Pharmacogenomics in type II diabetes mellitus management: Steps toward personalized medicine
title_fullStr Pharmacogenomics in type II diabetes mellitus management: Steps toward personalized medicine
title_full_unstemmed Pharmacogenomics in type II diabetes mellitus management: Steps toward personalized medicine
title_short Pharmacogenomics in type II diabetes mellitus management: Steps toward personalized medicine
title_sort pharmacogenomics in type ii diabetes mellitus management: steps toward personalized medicine
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3513204/
https://www.ncbi.nlm.nih.gov/pubmed/23226037
work_keys_str_mv AT averypeter pharmacogenomicsintypeiidiabetesmellitusmanagementstepstowardpersonalizedmedicine
AT mousashaymaas pharmacogenomicsintypeiidiabetesmellitusmanagementstepstowardpersonalizedmedicine
AT mousashakera pharmacogenomicsintypeiidiabetesmellitusmanagementstepstowardpersonalizedmedicine